Resources

Vyepti Mechanism of Action Video

Vyepti Administration Guide

Vyepti Administration Video

Vyepti Patient Starter Pack

Vyepti Patient IV Infusion Leaflet

Vyepti Patient Headache Diary

Vyepti IV Benefit Leavepiece

A propsective real-world analysis of intravenous eptinezumab migraine management: The first UK experience¹

Andreou AP, et al. 2025

Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study¹

Argoff C, et al. 2024

Persistence to anti-CGRP monoclonal antibodies with OnabotulinumtoxinA among patients with migraine: A retrospective cohort study¹

Charleston IV et al. 2023

Efficacy and safety of eptinezumab in patients with chronic migraine (PROMISE-2)¹

Lipton RB, et al. 2020. PROMISE 2

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)¹

Ashina M, et al. 2020

Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing¹

Dodick DW, et al. 2020

Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: Extension of a randomized controlled trial¹

Ashina M, et al. 2023

No “Wearing off” effect observed with eptinezumab in the preventive treatment of migraine¹

Cady R et al. Poster AAN 2023

A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II)¹

Barbanti P, et al. 2025

Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures¹

Goadsby PJ et al. 2023